Failed 2025

    Inspirna

    If you can't fund the Phase 3 you designed, the design was wrong. Downsize the trial or partner years earlier.

    TL;DR — Failure Post-Mortem

    Inspirna was a Biotech / Oncology startup founded in 2014 in USA. It raised $210M before collapsing in 2025 — 11 years of runway burned. IdeaProof's AI Failure Score: 72/100, driven by failed to raise phase 3 funding; folded before pivotal trial. The shutdown affected employees, investors, and the broader Biotech / Oncology ecosystem. This case study breaks down the timeline, root causes, competitors that won, and replicable lessons for founders validating similar ideas today.

    Why did Inspirna fail?

    Inspirna failed in 2025 after 11 years of operation, losing $210M in raised capital. The root cause was failed to raise phase 3 funding; folded before pivotal trial. Key lesson: If you can't fund the Phase 3 you designed, the design was wrong. Downsize the trial or partner years earlier.

    Verifiable facts
    Sourced
    Founded → Closed

    2014 → 2025

    Funding Raised

    $210M

    Industry

    Biotech / Oncology

    Country

    USA

    IdeaProof AI Failure Score

    72/100
    Market Fit Risk
    70
    Burn Rate Risk
    95
    Founder Risk
    45

    What Happened: The Timeline

    🚀

    2014

    Inspirna founded in USA. Positioned in biotech / oncology.

    💰

    2014-2016

    Raises $210M from Deerfield Management, Cormorant Asset Management, Woodline Partners.

    ⚠️

    2024

    Warning signs emerge: phase 3 financing round failed.

    💀

    2025

    Shutdown announced. Root cause: failed to raise phase 3 funding; folded before pivotal trial.

    Root Causes

    Phase 3 financing round failed
    Trial design too expensive for market
    No pharma partner
    Deerfield/Cormorant declined to bridge

    Inspirna (formerly Rgenta Therapeutics, then Rgenix) was a New York City oncology drug developer led by well-known executives and backed by Deerfield, Cormorant and Woodline, with ~$210M raised. It was preparing for a Phase 3 pivotal cancer trial when in March 2025 Endpoints News reported the company was folding after failing to raise the Phase 3 financing round. The Phase 3 was designed at scale for a broad population; investors preferred a smaller, targeted trial the company felt could not read out convincingly. Inspirna illustrates a common late-stage biotech failure mode: trial design mismatched with capital availability.

    Causal Chain

    Derived · heuristic

    This is our reading of the causal chain — separated from the verifiable facts above. Timeline dates, funding numbers and filings are facts (see methodology); root / proximate / terminal attribution is judgement based on public evidence.

    Root cause

    A combination of demand-side, execution, and capital-market pressures that this record documents without isolating a single dominant driver.

    Contributing factors
    • Phase 3 financing round failed
    • Trial design too expensive for market
    • No pharma partner
    • Deerfield/Cormorant declined to bridge
    Proximate cause

    2024: Warning signs emerge: phase 3 financing round failed.

    Terminal event

    2025: Shutdown announced. Root cause: failed to raise phase 3 funding; folded before pivotal trial.

    Base rates

    External sources

    A single failure is an anecdote. These base rates give you the denominator — how common this outcome is across all startups matching Inspirna's profile. Sources are third-party; we do not restate them as our own claims.

    ~97%
    industry

    of venture-backed consumer hardware startups do not reach a profitable exit within 10 years — hardware requires atypical capital efficiency to survive.

    PitchBook Emerging Tech Research (2023)
    ~70%
    industry

    of digital-health startups fail to reach breakeven; reimbursement complexity + regulatory approvals extend runway needs beyond typical VC horizons.

    Rock Health State of Digital Health (2023)
    ~90%
    all

    of startups ultimately fail — including ~10% that fail in the first year and the rest across the following decade.

    Startup Genome / CB Insights aggregate (2024)
    ~35%
    all

    of new US employer businesses survive past their 10th year (Bureau of Labor Statistics BED series).

    US Bureau of Labor Statistics — BED (2024)
    ~35%
    stage

    of Series A rounds ever graduate to Series B; the rest run out of runway or pivot without a follow-on.

    CB Insights Venture Capital Funnel (2023)

    Key Lessons Learned

    1. Phase 3 financing round failed

    Phase 3 financing round failed — a recurring pattern across biotech / oncology failures. Validate this risk before you scale.

    2. Trial design too expensive for market

    Trial design too expensive for market — a recurring pattern across biotech / oncology failures. Validate this risk before you scale.

    3. No pharma partner

    No pharma partner — a recurring pattern across biotech / oncology failures. Validate this risk before you scale.

    Frequently Asked Questions

    Sources & Confidence

    Every data point is tagged with its source type and our confidence in it. How we grade sources.

    Additional references
    Endpoints News

    Could This Failure Have Been Prevented?

    IdeaProof's AI validates market demand, competitive positioning, and business model viability in minutes — catching the exact issues that sank Inspirna.

    Related Failures

    iTeos Therapeutics

    $600M+ (public) · 2025

    GSK terminated TIGIT partnership after negative Phase 2 lung cancer data

    Spotted a factual error?

    Approved corrections are published in the public changelog with attribution.

    After Inspirna: hubs, comparisons and deep dives

    Compare the validation, funding and go-to-market choices that separate survivors from failures like Inspirna.